Table 1.
Baseline demographics and disease characteristics
| Dose escalation | Dose expansion | ||||
|---|---|---|---|---|---|
| Advanced solid tumorsa (n= 50) |
Ovarian cancer (n = 29) |
TNBC (n = 14) |
CRPC (n = 12) |
All (N = 105) |
|
| Sex, n (%) | |||||
| Male | 21 (42.0) | 0 | 0 | 12 (100) | 33 (31.4) |
| Female | 29 (58.0) | 29 (100) | 14 (100) | 0 | 72 (68.6) |
| Age, mean (SD), years | 57 (12) | 61(11) | 55 (11) | 68 (8) | 59 (12) |
| BMI, mean (SD), kg/m2 | 27(7) | 27 (6) | 27 (5) | 28 (3) | 27 (6) |
| Race/ethnicity, n (%) | |||||
| White | 35 (70.0) | 23 (79.3) | 12 (85.7) | 11 (91.7) | 81 (77.1) |
| Black | 2 (4.0) | 1 (3.4) | 2 (14.3) | 0 | 5 (4.8) |
| Hispanic | 6 (12.0) | 0 | 0 | 1 (8.3) | 7 (6.7) |
| Asian | 4 (8.0) | 3 (10.3) | 0 | 0 | 7 (6.7) |
| Otherb | 3 (6.0) | 2 (6.9) | 0 | 0 | 5 (4.8) |
| ECOG PS, n (%) | |||||
| 0 | 32 (64.0) | 16(55.2) | 6 (42.9) | 2 (16.7) | 56 (53.3) |
| 1 | 17 (34.0) | 13 (44.8) | 7 (50.0) | 9 (75.0) | 46 (43.8) |
| 2 | 1 (2.0) | 0 | 1 (7.1) | 1 (8.3) | 3 (2.9) |
| Number of prior lines of chemotherapy, median (range) | 3.5 (0–13) | 3.0 (1–18) | 5.5 (2–12) | 3.5 (1–9) | 4.0 (0–18) |
| Prior radiotherapy, n (%) | 24 (48.0) | 6 (20.7) | 10(71.4) | 7 (58.3) | 47 (44.8) |
CRPC castration-resistant prostate cancer, ECOGPS Eastern Cooperative Oncology Group performance status, TNBC triple-negative breast cancer
a
Tumor types included ovarian (n = 4), breast (n = 6), prostate (n = 2), colon (n = 9), rectal (n = 2), and small-cell lung cancers (n = 3), and other (n = 24)
b
“Other” includes two American Indian or Alaska native, one Afghan, one Sri Lankan, and one Middle Eastern